[{"data":1,"prerenderedAt":25},["ShallowReactive",2],{"$fudSwRFz9NuDp6cSmSy-e9dLf28KfGLKwx3b9eG3uXro":3},{"card":4,"examId":6,"chapterTitle":22,"prev":23,"next":24},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":16,"lectureRef":16,"storyRef":16,"chapterSlug":17,"sectionCode":18,"sectionTitle":19,"clusterSlug":20,"term":16,"sequenceOrder":16,"regionWeight":16,"revisionMark":16,"isActive":21},"ch5-070","touhan","PPA（塩酸フェニルプロパノールアミン）の代替成分として切り替えが指示されたのはどれか。",2,[10,11,12,13],"アミノピリン","クロルフェニラミンマレイン酸塩","プソイドエフェドリン塩酸塩（PSE）","スルピリン","four","2003年8月までに脳出血等の副作用症例が複数報告されたことから、厚生労働省は代替成分としてプソイドエフェドリン塩酸塩（PSE）等への速やかな切り替えを指示しました。",null,"chapter-5","5-IV","一般用医薬品に関する主な安全対策","anzen-taisaku",true,"第5章 医薬品の適正使用・安全対策","ch5-069","ch5-071",1784619074292]